Bristol-Myers Squibb Co. claims in a suit filed in U.S. District Court in Trenton, New Jersey, that a federal program empowering Medicare to negotiate certain drug prices is a “faux negotiation” that allows the government to set prices.

The suit, filed by Jones Day, follows previous legal challenges to the program from Merck and the U.S. Chamber of Commerce. Jones Day also represents Merck in the other litigation, while King & Spalding, along with Porter Wright Morris & Arthur of Dayton, Ohio, represent the U.S. Chamber of Commerce.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]